Abstract
UDP-glucose dehydrogenases (EC 1.1.1.22) are responsible for the conversion of UDP-glucose to UDP-glucuronic acid, a key precursor in the biosynthesis of glycoconjugates. Herein we report the discovery and characterization of a UDPglucose dehydrogenase (GbUGD) from Granulibacter bethesdensis, a bacterium originally isolated from the lymph nodes of patients with chronic granulomatous disease (CGD). The recombinant form of the protein was expressed in high yield and the purified enzyme showed highest activity at 37°C/pH 9.0 and was strongly inhibited by Zn2+ ions, sodium dodecyl sulfate (SDS) and urea. UDP-xylose, an allosteric feedback inhibitor, reduced significantly the activity of the enzyme. High activities were observed using the co-substrates UDP-glucose and NAD+, whereas no activity could be detected using other nucleotide sugars or NADP+ as potential alternative substrates. The high activity combined with the simple purification procedure used make GbUGD a valuable new alternative biocatalyst for the synthesis of UDP-glucuronic acid or the development of NAD+ regeneration systems.
Keywords: Granulibacter bethesdensis, UDP-glucuronic acid, UDP-glucose dehydrogenase.
Protein & Peptide Letters
Title:Discovery and Biochemical Characterization of UDP-Glucose Dehydrogenase from Granulibacter bethesdensis
Volume: 22 Issue: 7
Author(s): Shuang Wei, Anna Kulinich, Xu C. Duan, Li Liu and Josef Voglmeir
Affiliation:
Keywords: Granulibacter bethesdensis, UDP-glucuronic acid, UDP-glucose dehydrogenase.
Abstract: UDP-glucose dehydrogenases (EC 1.1.1.22) are responsible for the conversion of UDP-glucose to UDP-glucuronic acid, a key precursor in the biosynthesis of glycoconjugates. Herein we report the discovery and characterization of a UDPglucose dehydrogenase (GbUGD) from Granulibacter bethesdensis, a bacterium originally isolated from the lymph nodes of patients with chronic granulomatous disease (CGD). The recombinant form of the protein was expressed in high yield and the purified enzyme showed highest activity at 37°C/pH 9.0 and was strongly inhibited by Zn2+ ions, sodium dodecyl sulfate (SDS) and urea. UDP-xylose, an allosteric feedback inhibitor, reduced significantly the activity of the enzyme. High activities were observed using the co-substrates UDP-glucose and NAD+, whereas no activity could be detected using other nucleotide sugars or NADP+ as potential alternative substrates. The high activity combined with the simple purification procedure used make GbUGD a valuable new alternative biocatalyst for the synthesis of UDP-glucuronic acid or the development of NAD+ regeneration systems.
Export Options
About this article
Cite this article as:
Wei Shuang, Kulinich Anna, C. Duan Xu, Liu Li and Voglmeir Josef, Discovery and Biochemical Characterization of UDP-Glucose Dehydrogenase from Granulibacter bethesdensis, Protein & Peptide Letters 2015; 22 (7) . https://dx.doi.org/10.2174/0929866522666150526092818
DOI https://dx.doi.org/10.2174/0929866522666150526092818 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
Call for Papers in Thematic Issues
Therapeutic Proteins and Peptides of Plant Origin
Plants are still the major repository of biologically active substances. In the last two decades, however, natural peptides and proteins of plant origin have gained increasing attention due to their pharmacological activities over a variety of human illnesses, including those mediated by infections and parasitosis and those involving different cellular ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preface [Hot topic: Insulin Resistance and Impaired Coronary Endothelial Function (Guest Editor: Teruo Inoue)]
Current Drug Targets - Cardiovascular & Hematological Disorders Synthesis and Biological Evaluation of Benzodioxol Derivatives as Cyclooxygenase Inhibitors
Letters in Drug Design & Discovery Therapeutic Proteins and Nanotechnology: Immune Response and Stealth Bioengineered Constructs
Current Drug Metabolism Molecular Aspects of Melatonin Treatment in Tinnitus: A Review
Current Drug Targets The Gut and Intestinal Bacteria in Chronic Heart Failure
Current Drug Metabolism Anti-Viral Therapies for Hepatitis C Virus Infection: Current Options and Evolving Candidate Drugs
Letters in Drug Design & Discovery The Involvement of PPARs in the Causes, Consequences and Mechanisms for Correction of Cardiac Lipotoxicity and Oxidative Stress
Current Molecular Pharmacology Episcleral, Intrascleral, and Suprachoroidal Routes of Ocular Drug Delivery - Recent Research Advances and Patents
Recent Patents on Drug Delivery & Formulation Quantitative Structure - Activity Relationship (QSAR) Studies on Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
Current Medicinal Chemistry RNA Silencing in Plants: Mechanisms, Technologies and Applications in Horticultural Crops
Current Genomics Decoding the Mechanism of Drugs of Heterocyclic Nature against Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Biology and Natural History of Type 1 Diabetes Mellitus
Current Pediatric Reviews Cytokine and Nitric Oxide Production Following Severe Envenomation
Current Drug Targets - Inflammation & Allergy Drugs to Treat Neuroinflammation in Neurodegenerative Disorders
Current Medicinal Chemistry RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets
Current Pharmaceutical Design Molecularly Imprinted Polymer of Colocynthin, An Effective Tool for Quality Control of <i>Citrullus colocynthis</i> Extracts
Current Drug Discovery Technologies Protective Effect of Natural Antioxidants on Heart Against Ischemia-Reperfusion Damage
Current Pharmaceutical Biotechnology Genetic Polymorphisms in the Growth Hormone Receptor: Impact on Growth Response and Disease Susceptibility
Current Pharmacogenomics and Personalized Medicine Compound Libraries: Recent Advances and Their Applications in Drug Discovery
Current Drug Discovery Technologies Adjunctive Immunotherapy of Mycobacterial Infections
Current Pharmaceutical Design